Three 2026 studies tie Follistatin 344 to artery and prostate effects

The takeaway is that follistatin 344 made artery plaque smaller in a mouse model that is prone to high cholesterol. The study used mice that lack a receptor for clearing bad cholesterol, so they develop fatty deposits in large arteries much like people with a strong genetic risk for heart disease ¹. Researchers delivered a gene for follistatin 344 with a modified virus, then compared those mice with untreated animals. The treated mice had less aortic plaque, better plasma lipid profiles, and lower markers of inflammation in white fat, liver, and heart tissue ¹. The same study found more uncoupling protein 1, a sign that white fat was starting to act more like energy-burning brown fat ¹. The limitation is that this was a mouse study using a gene-delivery method, so the results do not establish a human effect.

The main finding is that follistatin improved blood vessel behavior in rats bred for high blood pressure. The researchers used spontaneously hypertensive rats, a standard model of essential hypertension, and treated them with an inactive solution, follistatin, or hydralazine, a standard blood pressure drug, for eight weeks ². They measured vascular function with a wire myograph, a device that tests how a small artery relaxes or contracts, and they checked markers of stress and browning in the fat that wraps around blood vessels. Follistatin reduced reactive oxygen species, molecules that damage vessels, and increased nitric oxide, a molecule that helps vessels widen ². It also made the perivascular fat show more brown-fat markers, which the authors linked to activin neutralization and AMPK activation, a cellular energy-sensing switch ². Hydralazine lowered blood pressure but did not produce the same vessel changes, suggesting the effect was not just from lower blood pressure ². The limitation is that the study was done in rats, and the results cannot be assumed to apply to human hypertension.

The caution from a third study is that follistatin can help prostate cancer cells survive when androgen-blocking drugs are used. This study did not test injected follistatin 344. It looked at follistatin produced by the prostate cancer cells themselves ³. Under anti-androgen therapy, cancer cells increased follistatin, which turned down BMP proteins, another group of growth-control proteins that help keep cells dependent on androgen ³. That shift raised a protein called SOX9 and gave the cells a more stem-like, resistant state, reducing response to enzalutamide ³. Follistatin also altered the tumor environment by promoting bone-breakdown activity and weakening T cell activity ³. In patient samples, higher follistatin tended to go with lower prostate-specific antigen (PSA), a marker of androgen-driven prostate cancer, and with poorer outcomes in enzalutamide-treated patients ³. The limitation is that this is a mechanistic and observational study, not a trial of follistatin 344 as a therapy.

Follistatin 344 works outside cells by grabbing myostatin and activins, two growth-control proteins in the transforming growth factor-beta family ⁴. In muscle, those proteins normally put the brakes on growth, so blocking them can shift the balance toward building muscle. In fat and vessels, activins can promote inflammation, oxidative stress, and a more rigid state ¹. When follistatin binds them, the same brake release appears to let fat tissue adopt a beige or brown state, which burns energy and produces vessel-friendly molecules ¹. That connection is why the two new studies looked at plaque and blood vessel tone after follistatin delivery. The prostate study shows the same growth-control removal can have a different outcome in a tissue that depends on those proteins to stay controlled ³.

For years, the strongest evidence came from animals engineered to make more follistatin 344 or similar follistatin. Pigs that expressed human follistatin 344 gained more skeletal muscle and had less fat than normal pigs ⁵. A 2026 review noted that human safety and efficacy data for follistatin 344 remain indirect ⁷. Follistatin is also known to affect fat and glucose control. In mice, follistatin and a related protein regulate fat mass and glucose handling in different ways ⁸, and elevated follistatin has been associated with worse glycemic control in some populations ⁹. The new artery studies fit this broader pattern, because they found effects in fat tissue and blood vessels, not just muscle ¹. The prostate study is the clearest mechanistic clue yet that the same pathways can support a cancer's ability to escape treatment, though that clue comes from tumor-produced follistatin rather than an injected peptide ³.

The safety picture for Follistatin 344 was already cautious, and the prostate paper gives researchers another reason to watch growth-related pathways carefully. A 2026 review of peptide therapies states that most human safety and efficacy data for follistatin 344 are indirect ⁷. Long-term removal of growth restraints such as myostatin and activin could theoretically support tumor growth in susceptible tissues, which is why research protocols tend to use short courses with monitoring ⁷. The new prostate cancer study adds a concrete example in one cancer type ³. There are also reports of eye complications at high doses. A 2020 case series described central serous chorioretinopathy, a fluid buildup under the retina, in people using high-dose follistatin 344, though the sample was small and retrospective ¹¹. Elevated follistatin has also been associated with worse glucose handling in some populations ⁹. The limitation is that these are separate lines of evidence, and they do not prove that an injected dose of follistatin 344 causes the same outcome in a given animal or person.

The biggest unknown is whether the artery benefits seen in mice and rats will appear in any human study. The gene-delivery method in the mouse paper is not a standard peptide injection, and the rat study used an animal model of hypertension ¹. The prostate finding is also not tied to an exact dose or duration of follistatin 344, because the cells increased their own follistatin under drug pressure ³. Separating the desired muscle and vascular effects from the possible cancer-supporting effects is still an open question, and the sources do not provide that answer. Longer animal studies with tissue-level monitoring would be needed before researchers can say whether any benefit outweighs the caution.